ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer-Reference-Cited by-同舟云学术

ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer

Published:2014-06 Issue:6 Volume:7 Page:1940-1955
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Van Schaeybroeck Sandra,Kalimutho Murugan,Dunne Philip D.,Carson Robbie,Allen Wendy,Jithesh Puthen V.,Redmond Keara L.,Sasazuki Takehiko,Shirasawa Senji,Blayney Jaine,Michieli Paolo,Fenning Cathy,Lenz Heinz-Josef,Lawler Mark,Longley Daniel B.,Johnston Patrick G.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference39 articles.

1. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer;Allen;Mol. Cancer Ther.,2012

2. c-Met ectodomain shedding rate correlates with malignant potential;Athauda;Clin. Cancer Res.,2006

3. STK33 kinase activity is nonessential in KRAS-dependent cancer cells;Babij;Cancer Res.,2011

4. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1;Barbie;Nature,2009

5. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function;Biscardi;J. Biol. Chem.,1999

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming therapy resistance in pancreatic cancer: New insights and future directions;Biochemical Pharmacology;2024-11

2. Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment;Cancers;2024-03-02

3. Targeting C21orf58 is a Novel Treatment Strategy of Hepatocellular Carcinoma by Disrupting the Formation of JAK2/C21orf58/STAT3 Complex;Advanced Science;2024-02-11

4. Tumor associated neutrophils governs tumor progression through an IL-10/STAT3/PD-L1 feedback signaling loop in lung cancer;Translational Oncology;2024-02

5. Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling;Frontiers in Pharmacology;2024-01-10